Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use
- 30 November 2018
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 94 (3) , 358-362
Abstract
One of the most promising developments in therapy for acute myeloid leukemia (AML) in recent years has been the combination of hypomethylating agents (HMA, either decitabine or 5‐azacytidine) with the Bcl‐2 inhibitor venetoclax (VEN). Although both classes of drugs have single‐agent activity in AML, the combination has resulted in high rates of complete remission (CR) both in the frontline and relapsed settings suggesting synergy between these two agents. Recent data have suggested that CR + CR with incomplete count recovery rate may exceed 70% for frontline VEN‐HMA. Moreover, this activity has been observed across various genetic subtypes of AML including those known to have very poor response to conventional chemotherapy. Although VEN has only recently obtained FDA approval for treatment of AML, there has been increasing on and off‐label use of this combination given its striking efficacy and excellent toxicity profile. In this article, we summarize the current available data on this combination and offer practical guidelines for management of patients receiving VEN‐HMA. Our recommendations are based on protocol guidelines, published data from clinical trials as well as from analysis of real world evidence from patients treated with this combination.Keywords
This publication has 17 references indexed in Scilit:
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b studyThe Lancet Oncology, 2018
- Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelinesJournal of Infection, 2018
- Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesAmerican Journal of Hematology, 2017
- Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic ModelThe Journal of Clinical Pharmacology, 2017
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous LeukemiaCancer Discovery, 2016
- Mitochondria—Judges and Executioners of Cell Death SentencesMolecular Cell, 2016
- A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patientsBlood, 2015
- BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem CellsCell Stem Cell, 2013
- Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemiaLeukemia & Lymphoma, 2013
- Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive modelHaematologica, 2008